Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
InMode ( (INMD) ) has shared an update.
On March 13, 2026, InMode Ltd. announced that its board had authorized a new share repurchase program covering up to roughly 10% of its total shares outstanding, or about 6.38 million ordinary shares. The buybacks will be funded from existing cash and executed in the open market or through other permitted methods, with flexibility to modify or discontinue the program at the company’s discretion.
The move follows approximately $127.4 million of share repurchases completed in 2025 and underscores management’s view that the current valuation makes buybacks an attractive use of capital. Despite a challenging macroeconomic backdrop and ongoing regional conflict, InMode reports strong cash generation and signals ongoing evaluation of further repurchase initiatives and other capital allocation options, a stance that may reassure investors about balance-sheet strength and shareholder-return priorities.
The most recent analyst rating on (INMD) stock is a Hold with a $16.50 price target. To see the full list of analyst forecasts on InMode stock, see the INMD Stock Forecast page.
Spark’s Take on INMD Stock
According to Spark, TipRanks’ AI Analyst, INMD is a Outperform.
The score is driven primarily by strong underlying financial quality (high margins, strong cash conversion, and a very conservative balance sheet). Offsetting that strength are weakened growth and profitability trends and a conservative 2026 outlook that implies flat revenue and lower margins/EPS. Technicals are mildly constructive and valuation is relatively low, but both are secondary to the near-term fundamental trajectory.
To see Spark’s full report on INMD stock, click here.
More about InMode
InMode Ltd., based in Yokneam, Israel, is a leading global provider of innovative medical technologies focused on devices that harness novel radio frequency technology. The company develops, manufactures, and markets minimally invasive RF-based systems used across plastic surgery, gynecology, dermatology, otolaryngology, and ophthalmology, targeting both emerging surgical procedures and enhancements to existing treatments.
Average Trading Volume: 992,397
Technical Sentiment Signal: Sell
Current Market Cap: $808.5M
Find detailed analytics on INMD stock on TipRanks’ Stock Analysis page.